D. E. Shaw & Co. Inc. Grows Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

D. E. Shaw & Co. Inc. lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 46.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,625 shares of the medical research company’s stock after purchasing an additional 7,837 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.09% of Bio-Rad Laboratories worth $8,090,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Metis Global Partners LLC grew its holdings in Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock valued at $234,000 after purchasing an additional 30 shares during the last quarter. Signaturefd LLC boosted its stake in Bio-Rad Laboratories by 13.2% in the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock worth $87,000 after buying an additional 31 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Bio-Rad Laboratories by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock worth $1,488,000 after purchasing an additional 32 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Bio-Rad Laboratories by 3.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Citigroup dropped their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. UBS Group dropped their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada lowered their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $327.40.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $242.94 on Friday. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of -3.74 and a beta of 1.00. The stock has a 50 day moving average of $243.51 and a 200-day moving average of $299.31. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52 week low of $215.38 and a 52 week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The business had revenue of $585.40 million during the quarter, compared to analyst estimates of $573.01 million. During the same quarter in the previous year, the firm posted $2.30 EPS. The business’s revenue for the quarter was down 4.2% compared to the same quarter last year. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.